258 related articles for article (PubMed ID: 30796625)
21. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
22. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
23. A triple combination 'nano' dry powder inhaler for tuberculosis: in vitro and in vivo pulmonary characterization.
Chogale MM; Dhoble SB; Patravale VB
Drug Deliv Transl Res; 2021 Aug; 11(4):1520-1531. PubMed ID: 34041715
[TBL] [Abstract][Full Text] [Related]
24. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles.
Wang Y; Kho K; Cheow WS; Hadinoto K
Int J Pharm; 2012 Mar; 424(1-2):98-106. PubMed ID: 22226876
[TBL] [Abstract][Full Text] [Related]
25. Design of ciprofloxacin-loaded nano-and microcomposite particles for dry powder inhaler formulations: preparation, in vitro characterisation, and antimicrobial efficacy.
Topal GR; Devrim B; Eryilmaz M; Bozkir A
J Microencapsul; 2018 Sep; 35(6):533-547. PubMed ID: 30213209
[TBL] [Abstract][Full Text] [Related]
26. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
27. Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery.
Bi R; Shao W; Wang Q; Zhang N
J Biomed Nanotechnol; 2009 Feb; 5(1):84-92. PubMed ID: 20055110
[TBL] [Abstract][Full Text] [Related]
28. Porous particles and novel carrier particles with enhanced penetration for efficient pulmonary delivery of antitubercular drugs.
Tse JY; Koike A; Kadota K; Uchiyama H; Fujimori K; Tozuka Y
Eur J Pharm Biopharm; 2021 Oct; 167():116-126. PubMed ID: 34363979
[TBL] [Abstract][Full Text] [Related]
29. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
Saboti D; Maver U; Chan HK; Planinšek O
J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
[TBL] [Abstract][Full Text] [Related]
30. Development of a new formulation of roflumilast for pulmonary drug delivery to treat inflammatory lung conditions.
Suzuki ÉY; Amaro MI; de Almeida GS; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2018 Oct; 550(1-2):89-99. PubMed ID: 30130605
[TBL] [Abstract][Full Text] [Related]
31. Preparation of Curcumin Solid Lipid Nanoparticles Loaded with Flower-Shaped Lactose for Lung Inhalation and Preliminary Evaluation of Cytotoxicity In Vitro.
Li N; Li X; Cheng P; Yang P; Shi P; Kong L; Liu H
Evid Based Complement Alternat Med; 2021; 2021():4828169. PubMed ID: 34745284
[TBL] [Abstract][Full Text] [Related]
32. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
[TBL] [Abstract][Full Text] [Related]
33. Optimization of a dry powder inhaler of ciprofloxacin-loaded polymeric nanomicelles by spray drying process.
Farhangi M; Mahboubi A; Kobarfard F; Vatanara A; Mortazavi SA
Pharm Dev Technol; 2019 Jun; 24(5):584-592. PubMed ID: 30431373
[TBL] [Abstract][Full Text] [Related]
34. Application of void forming index (VFI): Detection of the effect of physical properties of dry powder inhaler formulations on powder cohesion.
Maruyama S; Ando S; Yonemochi E
Int J Pharm; 2020 Oct; 588():119766. PubMed ID: 32800937
[TBL] [Abstract][Full Text] [Related]
35. Inhalable liposomes of Glycyrrhiza glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo pharmacodynamic studies.
Viswanathan V; Pharande R; Bannalikar A; Gupta P; Gupta U; Mukne A
Drug Dev Ind Pharm; 2019 Jan; 45(1):11-20. PubMed ID: 30122088
[TBL] [Abstract][Full Text] [Related]
36. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
[TBL] [Abstract][Full Text] [Related]
37. Preparation and optimization of a dry powder for inhalation of second-line anti-tuberculosis drugs.
Ranjan R; Srivastava A; Bharti R; Ray L; Singh J; Misra A
Int J Pharm; 2018 Aug; 547(1-2):150-157. PubMed ID: 29852204
[TBL] [Abstract][Full Text] [Related]
38. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
39. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
40. Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment.
Paul PK; Nakpheng T; Paliwal H; Prem Ananth K; Srichana T
Int J Pharm; 2024 Jun; 660():124309. PubMed ID: 38848797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
